- Home
- ROIV vs WSC Comparison
ROIV vs WSC Comparison
Compare ROIV & WSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- WSC
- Stock Information
- Founded
- ROIV 2014
- WSC 1944
- Country
- ROIV United Kingdom
- WSC United States
- Employees
- ROIV N/A
- WSC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- WSC Misc Corporate Leasing Services
- Sector
- ROIV Health Care
- WSC Industrials
- Exchange
- ROIV Nasdaq
- WSC Nasdaq
- Market Cap
- ROIV 8.4B
- WSC N/A
- IPO Year
- ROIV N/A
- WSC N/A
- Fundamental
- Price
- ROIV $10.15
- WSC $23.32
- Analyst Decision
- ROIV Buy
- WSC Buy
- Analyst Count
- ROIV 4
- WSC 8
- Target Price
- ROIV $17.50
- WSC $40.50
- AVG Volume (30 Days)
- ROIV 8.0M
- WSC 5.1M
- Earning Date
- ROIV 05-29-2025
- WSC 05-01-2025
- Dividend Yield
- ROIV N/A
- WSC 0.29%
- EPS Growth
- ROIV N/A
- WSC N/A
- EPS
- ROIV N/A
- WSC 0.15
- Revenue
- ROIV $122,585,000.00
- WSC $2,395,718,000.00
- Revenue This Year
- ROIV N/A
- WSC N/A
- Revenue Next Year
- ROIV N/A
- WSC $5.02
- P/E Ratio
- ROIV N/A
- WSC $155.94
- Revenue Growth
- ROIV 140.04
- WSC 1.31
- 52 Week Low
- ROIV $8.73
- WSC $21.91
- 52 Week High
- ROIV $13.06
- WSC $43.80
- Technical
- Relative Strength Index (RSI)
- ROIV 50.07
- WSC 34.70
- Support Level
- ROIV $9.90
- WSC $22.95
- Resistance Level
- ROIV $10.26
- WSC $26.07
- Average True Range (ATR)
- ROIV 0.47
- WSC 1.90
- MACD
- ROIV 0.06
- WSC -0.07
- Stochastic Oscillator
- ROIV 92.81
- WSC 19.72
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.